Debunking the debunker, by Joan Beal

"...Tony knew how to get around that problem of MS progression. He only enrolled young people and people with early RRMS in his Lemtrada trial. And voila! Success! It's amazing what drugs can do when you get rid of those pesky older and progressive patients. He saved them for the CCSVI trial, where the median age was 50, and most were progressive..."

"...The problem with using Lemtrada/Campath as an MS treatment was that it did not help people who were already progressive. In fact, as researchers were dismayed to find out, people with progressive MS disease worsened on the drug..."

Debunking the debunker.